GENERAL ATLANTIC, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001017645

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHigh Turnover how tags are computed

Q2 2026 · 12 positions · Total reported value $2.91B · Top-10 concentration 99.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 41.7% · 0 new · 4 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -5.4% · vs SPY -7.5% · Prev Value $2.91B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -6.8% · vs SPY -9.0% · Latest Value $2.44B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, GENERAL ATLANTIC, L.P. disclosed 12 equity positions with a combined reported value of $2.91B. The filing implies a focused portfolio: its ten largest positions account for 99.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / High Turnover.

The largest disclosed positions as of Q2 2026 were LFTO ($608.08M), DLO ($606.30M), CHYM ($435.40M). By sector, the heaviest allocations are Technology 33.0%, Financials 26.5%. Versus the prior quarter, allocation shifted toward Technology (+21.8pp), Health Care (+1.9pp) and away from Other (-6.0pp), Consumer Discretionary (-7.4pp).

Versus the prior quarter, GENERAL ATLANTIC, L.P. opened 0 new positions, trimmed 4 and fully exited 1, a turnover rate of 41.7% of positions. The portfolio's overlap with the prior quarter was 60% of names.

The largest new positions opened in Q2 2026 were LFTO ($608.08M), SPTX ($132.53M), PBLS ($42.11M).

Of the 1 positions fully exited versus the prior quarter, the largest were EWCZ ($75.78M), CNTA ($53.81M), BULL ($243.92K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • LFTO LIFTOFF MOBILE INC · $608.08M
  • SPTX SEAPORT THERAPEUTICS INC · $132.53M
  • PBLS PARABILIS MEDICINES INC · $42.11M

Fully Exited (vs previous quarter)

  • EWCZ EUROPEAN WAX CTR INC · prev qtr: $75.78M
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $53.81M
  • BULL WEBULL CORP · prev qtr: $243.92K

Insider Transactions (Form 4)

Latest GENERAL ATLANTIC, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-05 Buy Liftoff Mobile, Inc. 1,304,347 $23.00 SEC filing
2026-05-14 Buy ALKAMI TECHNOLOGY, INC. 675,000 $16.49 SEC filing
2026-05-13 Buy ALKAMI TECHNOLOGY, INC. 550,000 $16.63 SEC filing
2026-05-12 Buy ALKAMI TECHNOLOGY, INC. 750,000 $16.87 SEC filing
2026-05-06 Buy ALKAMI TECHNOLOGY, INC. 844,772 $16.63 SEC filing
2026-05-05 Buy ALKAMI TECHNOLOGY, INC. 700,000 $16.84 SEC filing
2026-05-04 Buy ALKAMI TECHNOLOGY, INC. 521,771 $16.92 SEC filing

All insider transactions →

Fund Profile

General Atlantic is an SEC-registered 13F filer. As of Q2 2026 it reported 12 US equity positions with a combined value of $2.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 12 positions · $2.91B reported value (Q2 2026)
  • Top 10 holdings = 99.0% of reported value
  • Largest position: LFTO (LIFTOFF MOBILE INC) at 20.9%
  • Average position size: $242.25M

Sector Tilt

  • Information Technology 33.0%
  • Financials 26.5%
  • Consumer Discretionary 21.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 1 added, 3 reduced, 3 exited
  • 5 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to be actively managing its portfolio with a focus on growth-oriented sectors such as Technology and Health Care. The addition of three new holdings and the significant increase in Alkami Technology Inc. suggests a bullish outlook on technology and fintech sectors. 2. Key Moves: - New Positions: LIFTOFF MOBILE INC (LFTO), SEAPORT THERAPEUTICS INC (SPTX), and PARABILIS MEDICINES INC COM (PBLS) were added, indicating a willingness to take on new risks and explore emerging companies. - Increased Positions: Alkami Technology Inc. (ALKT) saw a 26.4% increase in shares, signifying confidence in its growth potential. - Reduced Positions: PHARVARIS N V (PHVS) and NURIX THERAPEUTICS INC (NRIX) were trimmed, possibly due to valuation concerns or less optimism about their prospects. 3. Portfolio Structure: The fund is active, with a significant sector bias towards Technology and Health Care. The risk appetite seems to be higher than average, as indicated by the addition of new positions and the substantial increase in Alkami Technology Inc. shares. 4. Per-Holding One-Liner: - LFTO (LIFTOFF MOBILE INC): Mobile technology company; 'unverified' - DLO (DLOCAL LTD): Latin American fintech company; 'unverified' - CHYM (CHIME FINL INC): Digital banking platform; 'unverified' - ALKT (ALKAMI TECHNOLOGY INC): Fintech company offering digital banking solutions; 'unverified' - XP (XP INC): Fintech company offering digital banking services; 'unverified' - PHVS (PHARVARIS N V): Biopharmaceutical company; 'unverified' - SPTX (SEAPORT THERAPEUTICS INC): Biotechnology company focused on rare diseases; 'unverified' - NRIX (NURIX THERAPEUTICS INC): Biopharmaceutical company developing therapies for rare genetic disorders; 'unverified' - RVMD (REVOLUTION MEDICINES INC): Biopharmaceutical company developing therapies for cancer and rare diseases; 'unverified' - PBLS (PARABILIS MEDICINES INC COM): Biotechnology company focused on developing treatments for rare diseases; 'unverified' 5. One-Sentence Style Summary: The fund actively seeks growth opportunities in technology and biopharma sectors, adding new positions and increasing stakes in select companies while reducing exposure to others.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Technology 33.0%
Financials 26.5%
Health Care 18.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 25.32M $608.08M 20.92%
20.92%
New
2 46.66M $606.30M 20.86%
20.86%
Hold
3 21.26M $435.40M 14.98%
14.98%
Hold
4 19.38M $351.15M 12.08%
12.08%
Add
5 20.57M $334.41M 11.50%
11.50%
Hold
6 6.55M $226.53M 7.79%
7.79%
Reduce
7 6.10M $132.53M 4.56%
4.56%
New
8 3.03M $73.56M 2.53%
2.53%
Reduce
9 357.79K $67.01M 2.31%
2.31%
Reduce
10 1.54M $42.11M 1.45%
1.45%
New
11 5.32M $26.84M 0.92%
0.92%
Hold
12 2.47M $3.09M 0.11%
0.11%
Hold

FAQ

What did GENERAL ATLANTIC, L.P. buy in 2026-Q2?

In its 2026-Q2 13F filing, GENERAL ATLANTIC, L.P. reported 12 equity positions worth $2.91B in aggregate; its largest disclosed positions were LFTO ($608.08M), DLO ($606.30M), CHYM ($435.40M).

How large is GENERAL ATLANTIC, L.P.'s portfolio?

GENERAL ATLANTIC, L.P. reported $2.91B of long equity holdings across 12 positions as of 2026-Q2. Top-10 holdings account for 99.0% of reported value.

What is GENERAL ATLANTIC, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/general-atlantic/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →